Medtronic celebrates renal denervation hypertension data; Given Imaging touts GI imaging results;

 @FierceMedDev: Israel's growing medical device industry gains a public stage this week. More | Follow @FierceMedDev

 @MarkHFierce: W.L. Gore has the final piece in place for its REDUCE Clinical study, to test a new stroke prevention device. More | Follow @MarkHFierce

 @DamianFierce: WuXi AppTec is making a splash in biologics, launching a cGMP plant in China. More | Follow @DamianFierce

> Medtronic ($MDT) says it has generated major, long-term reductions in high blood pressure over two years in patients treated with the company's Symplicity renal denervation system. Item

> Israel's InSightec nailed down FDA approval to use its ExAblate MRI-guided focused ultrasound device to treat pain from bone metastases in patients who don't respond to or can't use radiation treatment for their pain. Item

> An analyst firm has launched a new study on how physicians and other medical professionals are taught to use new medical devices. Item

> French company Nicox is debuting its point-of-care diagnostic for acute conjunctivitis in the U.S. Item

> Given Imaging ($GIVN) is touting new studies it says shows the benefit of using high-resolution manometry to diagnose patients with anorectal and GI reflux disorders. Release

> California diagnostics startup Natera wants to change prenatal testing by analyzing DNA fragments. Story

Biotech News

 @FierceBiotech: Researchers seek new pancreatic cancer biomarkers. Item | Follow @FierceBiotech

 @JohnCFierce: In case you missed it Friday, my analysis on Q3 venture numbers (good) and top 10 deals of the quarter. Special Report | Follow @JohnCFierce

 @RyanMFierce: Quintiles reels in pharma business with IT game changers. More | Follow @RyanMFierce

> Orexigen says FDA nods support for a speedy review of Contrave. More

> Genzyme pays $22.5M upfront to bag Asian rights to Alnylam's hot ATTR program. Report

> Bayer nails promising PhIII results for new PAH contender riociguat. News

Pharma News

@FiercePharma: Merck is a champion donor, charity pub says. Ranks 2nd for corporate giving, as % of pretax profits.--Forbes. More | Follow @FiercePharma

> Pfizer snags new ADHD drug in $680M NextWave deal. Story

> Novartis balks at Eylea-vs.-Lucentis data. Article

> Turkey eyes a $23B pharma sector by 2023, up from $5B. News

> Generic savings tell a different patent-loss tale. Report

CRO News

> Lundbeck seeks partners on Alzheimer's drug after EMA rejection. Item

> Korean group enlists WCCT to spur drug development. More

> WuXi launches China's first GMP-friendly biologics plant. News

> Catalent looks to bridge industry, academia on drug delivery. Article

Biotech IT News

> Pfizer wins popularity contest in social media survey of patients. More

> Quintiles reels in pharma business with IT game changers. Story

> Appistry grabs distribution of MIT-Harvard genome toolkit. Report

> Big Pharma consortium to share cancer trial data. Article

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.